By Fineline Cube 
US major Eli Lilly and Company (NYSE: LLY) presented detailed results from the Phase III QWINT-1, QWINT-3, and QWINT-4 trials at the 85th ADA Scientific Sessions. The trials evaluated the efficacy of its investigational once-weekly insulin efsitora in adults with type 2 diabetes (T2D) across three distinct clinical scenarios: insulin-naïve patients (QWINT-1), patients with prior daily basal insulin use (QWINT-3), and those with prior basal-bolus therapy (QWINT-4).
Trial Outcomes
In each trial, efsitora achieved non-inferiority to daily basal insulin in terms of glycated hemoglobin (A1C) reduction:
- QWINT-1: At 52 weeks, A1C decreased by 1.31% in the efsitora group versus 1.27% in the insulin glargine group.
- QWINT-3: At 26 weeks, A1C reduction was 0.86% in the efsitora group compared to 0.75% in the degludec insulin group.
- QWINT-4: Both efsitora and insulin glargine groups achieved a 1.07% A1C reduction at week 26.
Safety Profile
Efsitora demonstrated a safety profile comparable to daily basal insulins across all trials.
Future Plans
Lilly plans to submit global regulatory filings for efsitora in T2D by the end of 2025.-Fineline Info & Tech